• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Celgene acquires Delinia, beats on Q4 earnings

January 27, 2017 By Sarah Faulkner

Celgene acquires Delinia, beats on Q4 earningsShares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results.

The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth of 17% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $1.61, ahead of consensus on The Street, where analysts were looking for sales of $3.0 billion.  Celgene also said that it expects to earn between $7.10 and $7.25 a share in 2017, while analysts forecast $6.55 apiece.

“2016 was an outstanding year of progress strengthening our commercial portfolio and advancing our early-, mid- and late-stage pipeline,” CEO Mark Alles said in prepared remarks. “We expect our business momentum and significant near-term catalysts to drive high-growth through 2017 and beyond.”

Celgene said it expects to post adjusted EPS of $5.94 on sales of $11.2 million for the full year.

CELG shares were trading at $112.81 apiece today in mid-afternoon trading, up 1.1%.

This month, Celgene acquired biotech Delinia Inc., for an initial payment of $300 million. Delinia could also get an additional $475 million, contingent on development, regulatory and commercial milestones for its DEL-106 immunotherapeutic.

The companies plan to close the transaction within the 1st quarter this year, according to Celgene.

“Delinia is at the forefront of advancing new approaches to treating patients with severe and debilitating autoimmune diseases,” Celgene’s president of research and early development Rupert Vessey said. “We look forward to progressing DEL106 into the clinic next year.”

“We are delighted to enter into this transaction with Celgene,” Delinia CEO Dr. Saurabh Saha added. “Their expanding inflammation and immunology franchise and strong commitment to scientific innovation makes them an ideal company to continue to move DEL106 forward.”

Filed Under: Featured, MassDevice Earnings Roundup, Mergers & Acquisitions Tagged With: Celgene

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS